David Ozretic

Dr. David Ozretic

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
IKIvana Karmelić
Ivana Karmelić
IRIvana Rubić
Ivana Rubić
KSKatarina Starcevic
Katarina Starcevic
DODavid Ozretic
David Ozretic
ZPZdravka Poljaković
Zdravka Poljaković
Dragana FabrisDragana Fabris
Dragana Fabris
Ischemic stroke is one of the leading causes of death and permanent disability in the world. Rapid diagnosis and intervention are crucial for reducing its consequences on individuals and societies. Therefore, identifying reliable biomarkers for early detection, prognostics, and therapy can facilitate the early prediction and prevention of stroke. Metabolomics has been shown as a promising tool for biomarker discovery since many post-ischemic metabolites can be found in the plasma or serum of the patient. In this research, we performed a comparative targeted metabolomic analysis of stroke thrombi, stroke patient serums, and healthy control serums in order to determine the alteration in the patients’ metabolomes, which might serve as biomarkers for early prediction or stroke prevention. The most statistically altered metabolites characterized in the patient serums compared with the control serums were glutamate and serotonin, followed by phospholipids and triacylglycerols. In stroke thrombi compared with the patients’ serums, the most significantly altered metabolites were classified as lipids, with choline-containing phospholipids and sphingomyelins having the highest discriminatory score. The results of this preliminary study could help in understanding the roles of different metabolic changes that occur during thrombosis and cerebral ischemia and possibly suggest new metabolic biomarkers for ischemic stroke.

21 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
IKIvana Karmelić
Ivana Karmelić
IRIvana Rubić
Ivana Rubić
KSKatarina Starcevic
Katarina Starcevic
DODavid Ozretic
David Ozretic
ZPZdravka Poljaković
Zdravka Poljaković
Dragana FabrisDragana Fabris
Dragana Fabris
Ischemic stroke is one of the leading causes of death and permanent disability in the world. Rapid diagnosis and intervention are crucial for reducing its consequences on individuals and societies. Identifying reliable biomarkers for early detection, prognostics and therapy is a criti-cal imperative for improving the stroke patient treatment. Metabolomics has been shown as a promising tool for biomarker discovery since many of the post-ischemic metabolites can found in the plasma or serum of the patient. In this research, we have performed comparative targeted metabolomic analysis of stroke thrombi, patient serums and healthy control serums in order to determine the alteration in the patients’ metabolome. The most statistically altered metabolites characterized in patient compared to control serums were glutamate and serotonin, followed by several lipid metabolites (phospholipids and triacylglycerols) and glucose. In stroke thrombi compared to patient’s serums, the most significantly altered metabolites were classified as li-pids, with choline-containing phospholipids and sphingomyelins having the highest discrimi-natory score. The results of this study could help in understanding the roles of different meta-bolic changes occurring during thrombosis and cerebral ischemia and possibly suggest new metabolic biomarkers of the ischemic stroke.

11 April 2024 in Lijecnicki Vjesnik
Verified
Journal Article
Open access
PDF file
APAna Hrkać Pustahija
Ana Hrkać Pustahija
DODavid Ozretic
David Ozretic
Nasljedne metaboličke bolesti pripadaju skupini od više od 8.000 monogenski nasljednih bolesti, a prema online bazi podataka o nasljednim metaboličkim bolestima (IEMbase), do sada ih je poznato oko 1.900. Najčešće su uzrokovane patogenim varijantama...